TY - JOUR
T1 - Identification of tetrapeptides from a mixture based positional scanning library that can restore nM full agonist function of the L106P, I69T, I102S, A219V, C271Y, and C271R Human Melanocortin-4 Polymorphic Receptors (hMC4Rs)
AU - Haslach, Erica M.
AU - Huang, Huisuo
AU - Dirain, Marvin
AU - Debevec, Ginamarie
AU - Geer, Phaedra
AU - Santos, Radleigh G.
AU - Giulianotti, Marc A.
AU - Pinilla, Clemencia
AU - Appel, Jon R.
AU - Doering, Skye R.
AU - Walters, Michael A.
AU - Houghten, Richard A.
AU - Haskell-Luevano, Carrie
PY - 2014/6/12
Y1 - 2014/6/12
N2 - Human obesity has been linked to genetic factors and single nucleotide polymorphisms (SNPs). Melanocortin-4 receptor (MC4R) SNPs have been associated with up to 6% frequency in morbidly obese children and adults. A potential therapy for individuals possessing such genetic modifications is the identification of molecules that can restore proper receptor signaling and function. These compounds could serve as personalized medications improving quality of life issues as well as alleviating diseases symptoms associated with obesity including type 2 diabetes. Several hMC4 SNP receptors have been pharmacologically characterized in vitro to have a decreased, or a lack of response, to endogenous agonists such as α-, β-, and γ2-melanocyte stimulating hormones (MSH) and adrenocorticotropin hormone (ACTH). Herein we report the use of a mixture based positional scanning combinatorial tetrapeptide library to discover molecules with nM full agonist potency and efficacy to the L106P, I69T, I102S, A219V, C271Y, and C271R hMC4Rs. The most potent compounds at all these hMC4R SNPs include Ac-His-(pI)DPhe-Tic-(pNO2)DPhe-NH2, Ac-His-(pCl)DPhe-Tic-(pNO2)DPhe-NH2, Ac-His-(pCl)DPhe-Arg- (pI)Phe-NH2, and Ac-Arg-(pCl)DPhe-Tic-(pNO2)DPhe-NH 2, revealing new ligand pharmacophore models for melanocortin receptor drug design strategies.
AB - Human obesity has been linked to genetic factors and single nucleotide polymorphisms (SNPs). Melanocortin-4 receptor (MC4R) SNPs have been associated with up to 6% frequency in morbidly obese children and adults. A potential therapy for individuals possessing such genetic modifications is the identification of molecules that can restore proper receptor signaling and function. These compounds could serve as personalized medications improving quality of life issues as well as alleviating diseases symptoms associated with obesity including type 2 diabetes. Several hMC4 SNP receptors have been pharmacologically characterized in vitro to have a decreased, or a lack of response, to endogenous agonists such as α-, β-, and γ2-melanocyte stimulating hormones (MSH) and adrenocorticotropin hormone (ACTH). Herein we report the use of a mixture based positional scanning combinatorial tetrapeptide library to discover molecules with nM full agonist potency and efficacy to the L106P, I69T, I102S, A219V, C271Y, and C271R hMC4Rs. The most potent compounds at all these hMC4R SNPs include Ac-His-(pI)DPhe-Tic-(pNO2)DPhe-NH2, Ac-His-(pCl)DPhe-Tic-(pNO2)DPhe-NH2, Ac-His-(pCl)DPhe-Arg- (pI)Phe-NH2, and Ac-Arg-(pCl)DPhe-Tic-(pNO2)DPhe-NH 2, revealing new ligand pharmacophore models for melanocortin receptor drug design strategies.
UR - http://www.scopus.com/inward/record.url?scp=84902491258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902491258&partnerID=8YFLogxK
U2 - 10.1021/jm500064t
DO - 10.1021/jm500064t
M3 - Article
C2 - 24517312
AN - SCOPUS:84902491258
SN - 0022-2623
VL - 57
SP - 4615
EP - 4628
JO - Journal of medicinal chemistry
JF - Journal of medicinal chemistry
IS - 11
ER -
